CRISPR therapy shows promise in early trial for fatal muscle disease
Disease control
Ongoing
This early-phase study tested a new gene editing treatment called HG302 in 4 boys with Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease. The therapy uses CRISPR technology to fix the genetic error and help muscles produce dystrophin, a protein essential for musc…
Early phase 1 • Sponsor: HuidaGene Therapeutics Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC